Synergy Rx Recalls Betamethasone Creams and Ointments for Sterility Concerns
Synergy Rx is recalling various betamethasone cream and ointment products due to a lack of assurance of sterility and CGMP deviations.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility, which is a significant quality issue but does not meet the criteria for Severe (Class II with hospitalization) or Critical (Class I).
Plain-English summary
Synergy Rx is recalling multiple prescription-only betamethasone cream and ointment products, including BL 20%/4% Cream and various BLT combinations. The recall is being conducted because of a lack of assurance of sterility and Current Good Manufacturing Practice (CGMP) deviations.
The affected products were distributed nationwide within the United States. The recall covers all lots of the listed products. No specific illness or injury reports are mentioned in the source text.
Consumers and healthcare providers should stop using these products and contact Synergy Rx or their healthcare provider for further instructions.
The recalled product
- Product
- BL 20%/4% CREAM, BLT 20%/6%/4% CREAM, BLT 20%/6%/6%, BLT 20% 8% 4% CREAM, BLT 20% 8% 4% OINTMENT, BLT 20% 8% 6% CREAM, BLT 20%/ 8% /8% OINTMENT, BLT 20%/ 8% /8% CREAM, BLT 20%/ 7%/ 7% CREAM, BLT 20%/ 10%/ 4% CREAM, BLT 20%/ 10%/ 10% CREAM, BLT 20%/ 20%/ 10% OINTMENT,BLT 7%…
- Manufacturer
- Synergy Rx
- Category
- Drug — Topical Steroids
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 81 recalled by Synergy Rx under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 81 products in this recall →Related recalls
Same manufacturer · Synergy Rx
See all →- SevereSynergy Rx Recalls Lidocaine Creams Due to Sterility Assurance Issues
FDA (Drugs) · 2017-03-22
- HighSynergy Rx Recalls Ultra Lite Cream Due to Sterility Concerns
FDA (Drugs) · 2017-03-22
- SevereSynergy Rx Recalls Lactic Acid Solution Due to Sterility Concerns
FDA (Drugs) · 2017-03-22
- HighSynergy Rx Modified Jessner Peel Recalled for Sterility Assurance Issues
FDA (Drugs) · 2017-03-22
- SevereSynergy Rx Recalls CLEAR 2 Due to Sterility Assurance Concerns
FDA (Drugs) · 2017-03-22
Same hazard · sterility
See all →- SevereFDA Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2026-10-28
- SevereHeparin Sodium Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-10-28
- SevereHouston Rx LLC Recalls Tirzepatide/Niacinamide Vials Due to Sterility Concerns
FDA (Drugs) · 2026-10-21
- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereEssential Wellness Pharma Recalls Dexamethasone Ointment Due to Sterility Concerns
FDA (Drugs) · 2015-11-25
- SevereFDA Recalls Betamethasone Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-05-22
- SeverePhenol Injectable Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2014-01-22
- HighBetamethasone Dipropionate Ointment 0.05% recalled for manufacturing compliance failures
FDA (Drugs) · 2022-05-11
- SevereCantrell Recalls Neostigmine Methylsulfate Injection Due to Sterility Concerns
FDA (Drugs) · 2017-08-16
- SeverePharmedium Recalls Dexamethasone Sodium Phosphate Infusions Due to Sterility Concerns
FDA (Drugs) · 2018-02-28